Improving drug trials for mild to moderate Alzheimer's disease.
Over the last two decades, numerous studies have been conducted on subjects with mild to moderate Alzheimer's disease. The objective of this paper was to review concerns raised in the literature about the design and methodology of these clinical trials and to make recommendations to deal with the limitations identified. Concerns raised in the literature include the following: undue focus on statistical rather than clinical significance; the need for further pharmacoeconomic evaluations; the nonrepresentativeness of the study populations; perceived inadequacies in the direct-comparison studies conducted to date; the limitations of open-label extension studies; the inability of standard psychometric tools to document all the relevant treatment effects; the ethics of placebo-controlled trials; and, problems caused by the actions of the regulatory authorities. Recommendations are made to deal with the issues raised.
Hogan
David B
DB
Health Sciences Centre, University of Calgary, Calgary, Alberta, Canada.
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D002986:Clinical Trials as Topic / Q000941:ethics / Q000379:methods* / Q000592:standards*; D003362:Cost-Benefit Analysis; D003627:Data Interpretation, Statistical; D017277:Drug Approval / Q000379:methods; D017850:Economics, Pharmaceutical / Q000592:standards / Q000639:trends; D006801:Humans; D009483:Neuropsychological Tests / Q000592:standards; D010043:Outcome and Process Assessment, Health Care / Q000379:methods / Q000592:standards; D015983:Selection Bias